



Pharmacy Trends, Issues and Forecasts

October 8, 2026

Webinar Logistics

- **Send us your questions.** Use the “Q&A” feature at the bottom of the screen to send speakers your questions throughout today’s presentation.
- **Today’s forum is being recorded.** A copy of the slides and recording will be shared with PQA members within a week.
- **Give us your feedback.** A quick survey will launch at the end of today’s webinar.
- **Please disable all AI-powered notetakers.** This policy helps safeguard proprietary member-only and confidential information shared during this webinar.

Presenter



Scott Biggs
Director of the Supplier Services Group
IQVIA



2026 Pharmacy Trends, Issues and Forecasts

Prepared for PQA

Thursday, October 8, 2026

Presented by: Scott Biggs, Director, Supplier Services, IQVIA

Prepared by: David Mennen, Scott Biggs





Agenda

- Introduction
- Current Market Performance
- Retail Pharmacy and Rural Health
- Generics
- GLP-1s
- On the Radar
- Wrap-up

An abstract graphic on the left side of the slide, featuring a circular area filled with glowing blue waves and dots, creating a sense of motion and data flow.

Disclaimer slide

A large, solid blue circle is positioned on the right side of the slide, partially cut off by the edge.

Disclaimer

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third party sources or data.


As with any attempt to estimate future events, the forecasts, projections, conclusions, and other information included herein are subject to certain risks and uncertainties, and are not to be considered guarantees of any particular outcome.

All reproduction rights, quotations, broadcasting, publications reserved. No part of this presentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IQVIA.


Copyright © 2026 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.



Current Market Performance




Market growth remains positive, but momentum has moderated in 2026



Data Source: IQVIA National Sales Perspective


Volume continues to drive market expansion as pricing becomes a headwind

Total Market Sales \$ (in Billions) and Growth



Data Source: IQVIA National Sales Perspective




Total Market Sales \$ Growth Contribution



YTD Growth is shifting away from Retail and towards Mail and Non-Retail channels

Sales Growth


Sales \$ in Billions



Data Source: IQVIA National Sales Perspective

Retail growth has slowed sharply as price deflation offsets underlying demand

U.S. Retail Sales Growth Contributions MAT Jun 2024 – MAT Jun 2026






Data Source: IQVIA National Sales Perspective

MAT Jun 2025 MAT Jun 2026

Retail YTD weakness is being driven primarily by Chain & Mass and Independent performance


Sales Growth

Sales \$ in Billions



Data Source: IQVIA National Sales Perspective


Home Health and Clinics remain the fastest-growing Non-Retail channels



Data Source: IQVIA National Sales Perspective

Retail sales growth remains heavily dependent on GLP-1 demand; without them, Retail sales would be negative

MAT Jun 2026 Sales \$ Growth Contribution by Channel




Data Source: IQVIA National Sales Perspective

Anti-Obesity has emerged as a top-tier market segment, displacing Respiratory Agents


MAT June 2026 Top 6 Therapy Sales \$ Share:

63.6%

Up 6.4 percentage points since MAT June 2021




Top 6 Therapies = \$323.1B



MAT Jun 2021


Top 6 Therapies = \$606.6B



MAT Jun 2026


The top product in 1992 generated \$1.9B in sales; the top product today, Mounjaro, generates over 21 times that

Top Product by Year based on Sales \$



As a percent of total sales, the top 10 branded products are huge drivers to market performance

Top 10 Brand Products as a Percent of Total Sales




In the last 5 years the market has experienced a 1000% increase in products exceeding \$15 Bn annually in sales

Sales Range	1995	2000	2005	2010	2015	2020	2025	5 Year Increase

The era of the Mega-Blockbuster is upon us!


A small group of branded products is driving a disproportionate share of industry growth

Total Market Sales \$ Growth




The top three fastest growing products are GLP-1s; specialty products round out the remaining top 10

Top 10 fastest growing products based on MAT June 2026 absolute sales \$ growth




IRA-negotiated products are creating a meaningful drag on overall market growth

Quarterly Market Sales Trends




YoY Growth Trends



Data Source: IQVIA National Sales Perspective

Retail absorbs the greatest financial impact from IRA negotiated products




Notes:

- Only the Brand molecule of the IRA MFP product was analyzed
- Other factors impacting the analysis could be loss of exclusivity
- The +6.3% market growth is made up of a contribution of:
 - **+11.3% growth in Rest of Market**
 - **-5% growth for the IRA MFP products**

Data Source: IQVIA National Sales Perspective




Retail Pharmacy and Rural Healthcare




Long-Term Care continues to gain adjusted Rx share as Mail declines and Retail share is flat

 Adjusted Rxs


Retail




Mail



LTC




 Adjusted Rx Share




Source: IQVIA, RxInsights, June 2026

Chain scripts have turned negative as store closures reshape the Retail landscape



7,940 ***fewer*** pharmacies than seven years ago
Net loss of 2,092 in 2025 and YTD 2026






Adjusted Rxs per Patient

- 1 **Indep: 33.5 Rxs/patient**
Generic: 21.2 (1st)
Brand: 6.6 (1st)
Other 5.7 (1st)
- 2 **Food: 29.7 Rxs/patient**
Generic: 19.5 (2nd)
Brand: 5.4 (Last)
Other 4.8 (Last)
- 3 **Mass: 28.8 Rxs/patient**
Generic: 17.9 (3rd)
Brand: 5.7 (2nd)
Other 5.2 (3rd)
- 4 **Chain: 28.2 Rxs/patient**
Generic: 17.8 (Last)
Brand: 5.5 (3rd)
Other 4.9 (3rd)

Source: IQVIA, RxInsights, June 2026

Med D and 3rd Party payers are capturing Retail share as discount cards have collapsed -13.5%

Adjusted Rx data is based on Moving Annual Total, June 2026



Source: IQVIA, RxInsights, June 2026


Each pharmacy closure now disrupts more than twice as many patients as in 2018

STRUCTURAL DRIVERS

Fewer Access Points

Nearly 8K fewer active retail pharmacy locations since 2018


Active Retail Pharmacies by Year



More Claims per Pharmacy

Remaining pharmacies now carry more prescription volume

Average Claim Count per Pharmacy Closure (1 Year Lookback)




RESULTING PATIENT IMPACT

Higher Patient Disruption per Closure



Average patients affected per pharmacy closure more than doubled

Average Patient Count per Pharmacy Closure (1 Year Lookback)




NPs/PAs are increasingly making up a larger proportion of providers, especially in rural areas

NP/PA Provider & Claim Proportion Over Time by RUCA
(RUCA Based on Provider Zip)




Research activity for GLP-1s is similar across geographies

Average Provider AIM Interactions by County Rurality
(Limited to GLP-1 related research; Jun 2018 – Jan 2026)



Provider AIM Interactions by County Rurality
(Limited to GLP-1 related research; Jun 2018 – Jan 2026)




Source: Audience Identity Manager® XR (AIM XR), County Health Rankings. Limited to counties with ≥ 25 providers and $\geq 1,000$ population, $n=2,002$ counties representing ~ 97% of US population and 1.4 million providers.

The vast majority of referrals went to cardiologists in metro areas despite location of referring provider

Primary Care Referrals to Cardiology Between RUCA Categories
(CY 2025, 9.1 M Patient Referrals)


Proportion of Primary Care Referrals to Cardiology to Metro Areas by originating RUCA
(CY 2025, 9.1 M Patient Referrals)




Access to acute care services declines as county rurality increases

Rural counties have 80% less facilities and 50% less providers

Average Count of Acute Care Services
Per County by Rurality
(2025)




Acute Care Beds and Provider Count
Per 100K Population by Rurality
(2025)



County Rurality	<25%	25%-49.9%	50%-74.9%	>75%
# Counties	510	579	588	814
# Population	239 M	46 M	26 M	14 M




Generics




Generics at a glance

Generic Rx %




Generic Sales %



57.8B


Generic sales in
MAT Jun 2026

Generic Sales Growth



Generic Rx Growth

Generic Rx (in Billions)



Unadjusted Adjusted

Generic Deflation

-7.8% YoY August generic oral deflation, down 40 bps from July

Source: August Gx Auditor: Despite -7.8% Deflation, Distributors Remain Stable, released September 14, 2026, Nephron Healthcare Investment Research

Generic Approvals

39% of ANDAs approved since 2013 have not launched

Based on IQVIA research of FDA Orange Book, SMART NSP, SMART US Launch Edition

Generic and Biosimilar Savings


\$492B Total Generic and Biosimilar Savings in 2025

Source: <https://accessiblemeds.org/resources/reports/2026-savings-report/>

Two blockbuster brands now generate more revenue than the entire generic market

2018

The Top
7 Brand
Products =
\$55.0B in Sales




Entire Generic Market
= **1,044**
Molecules and
\$55.7B in Sales




2021

The Top
3 Brand
Products =
\$55.2B in Sales




Entire Generic Market
= **1,072**
Molecules and
\$53.6B in Sales



MAT June 2026

The Top
2 Brand
Products =
\$85.5B in Sales



Entire Generic Market
= **1,120**
Molecules and
\$57.8B in Sales





 = 50 Generic Molecules



Price deflation is consuming 370%+ of generic gains while brands grow 9.5% on volume momentum

U.S. Total Market Generic and Brand Sales Growth Contributions MAT June 2026

Generics




Brands






GLP-1s




Nearly half of all market growth is now attributable to GLP-1 products

GLP-1 Sales Impact; MAT June




Diabetes GLP-1 Sales \$




Weight Loss GLP-1 Sales \$





What % of sales growth are GLP-1s?



Sales Distribution



Mass merchandisers capture a disproportionate share of GLP-1 demand while Independents lag




IQVIA's data shows that 35.3% of Independent stores do not fill weight loss GLP-1 products, down from 42.7% in Q1 2026



Business Rules


- Using IQVIA data, stores must have filled 1,000 or more Rx's in each quarter of the observation period
 - Observation Period: 2025 Q1 through 2026 Q2
- Each store had to have filled less than 10 Rx's for the specified category of drugs in each quarter

% of
Stores
not
filling
Rx's



The oral era begins as the Wegovy pill reshapes GLP-1 category and broadens the obesity market playbook


Early demand points to convenience and access as the next battleground in obesity treatment



*Foundayo Totall Promo data based on two months of available data

Competition in the oral GLP-1 market is accelerating following the launch of Oral Wegovy and Eli Lilly's Foundayo


Oral asset approval in the GLP-1 space marks a critical inflection point for market entry and differentiation




GLP-1s now command 65% of diabetes sales, having displaced insulin from 38% to under 10% market share in five years



Diabetes Sales Share by Type



Diabetes Rx Share by Type




Traditional diabetes therapies GLP-1 agonists SGLT-2 inhibitors DPP-IV inhibitors Insulins Other

GLP-1s continue to gain diabetes sales-dollar share across retail classes of trade



Diabetes Sales Share by Type – Retail Class of Trade




Traditional diabetes therapies GLP-1 agonists SGLT-2 inhibitors DPP-IV inhibitors Insulins Other

GLP-1s share of diabetes Rx is rising across all channels, with Food leading at 31.2% and Independents lagging at 20.8%



Diabetes Rx Share by Type – Retail Class of Trade



What's next? The possible expansion of the market beyond GLP-1s and obesity indications

Neurodegenerative Diseases

GLP-1s linked to reduced incidence of dementia, Alzheimer's, and stroke with neuroprotective effects

Respiratory Disorders

GLP-1s being explored in respiratory with potential to address systemic inflammation

Women's Health

GLP-1s associated with improved fertility and ovulation and lower cardiac risk in women with PMOS



Mental Health

Human trials suggest potential for GLP-1s to improve depressive symptoms



Substance Use Disorders

Links found between GLP-1s and reduced alcohol consumption, opioid overdose risk, and tobacco use

Cancer

GLP-1s associated with: decreased risk of prostate cancer progression, endometrial cancer, and obesity-related cancers

With a pipeline of over 200 molecules, the growth of obesity medicines will continue for the foreseeable future



Clinical trials are underway to understand GLP-1s as treatment in combination with other drugs

Science links obesity and metabolic dysregulation both by accumulation of extra fat as well as low grade inflammation



Immune pathway overlap
Shared immune-mediators amplify immune axes



Phenotype plasticity
Obesity alters immune disease phenotype



Weight-dependent pharmacology
Lower serum drug level, altered pharmacokinetics




Microbiome dysbiosis
Fuelling pathogenesis of immune disorders




Biomechanical stress
Strain on joints drives mechano-inflammation

TOGETHER-PsA
Endpoint Achieved by %
Patients, Wk36



TOGETHER-PsO
Endpoint Achieved by %
Patients, Wk36



Talz Only Talz + Zepbound

ACR: American College of Rheumatology; PASI: Psoriasis Area and Severity Index; HAD-QI: Health Assessment Questionnaire Disability Index; FACIT: Functional Assessment of Chronic Illness Therapy; DLQI: Dermatology Life Quality Index; sPGA: static Physician Global Assessment | Source: Lilly trial [result announcements](#)

The Part D Bridge Program will have a longstanding impact on the obesity medicine market

Program Summary


- Bridge will run from Jul 2026-Dec 2027 with BALANCE scheduled to start January 2028
- Prior authorization required for PDP and MA-PDP
 - BMI ≥ 35 OR
 - BMI ≥ 30 with CKD 3a+, uncontrolled hypertension, or heart failure diagnosis OR
 - BMI ≥ 27 with prediabetes, symptomatic peripheral artery disease, previous stroke, or previous myocardial infarction

Novo and Lilly agreed to \$245/month prices with patients paying \$50/month OOP


IQVIA is already seeing sizeable demand for the Part D Bridge program. Key questions include:

- How will payers respond to the Bridge program?
- How many new patients ages 65+ will initiate treatment?
- How will share play out across brands?

Paid Claims




Unpaid Claims



*Note: 4 Key GLP-1 brands Zepbound, Wegovy, Wegovy Pill, Foundaro | Based on Medicare D mode payer for the quarter; graph displays claim level payer. Unknown payer is removed from claim-level analysis.
Source: IQVIA U.S. Thought Leadership & Innovation and Market Access Strategy Consulting Analysis; LAAD Rx claims*




On the Radar



Drug Shortages and Inspections

Current Drug Shortages by Year Reported




Current Drug Shortages
73

FDA Drug Inspections



1,012

through 10 months of
Fiscal Year 2026




**Lowest total through 10
months since 2021**

Top Therapies by # of Shortages



Length of Time in Shortage


- 90 days or Less
- 1-2 Years
- > 2 Years
- 91 to 180 days



Data Sources: <https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm> and <https://datadashboard.fda.gov/ora/cd/inspections.htm>, data pulled 7/28/2026

TrumpRx.gov volume is climbing, and branded products account for nearly 93% of adjusted Rx's

TrumpRx.gov Adjusted Rx's



of all scripts are processed for a branded product

TOP FIVE BRANDED PRODUCTS



TOP FIVE GENERIC PRODUCTS



Scale today | Patient-direct access is broadening, but true DTP fulfillment remains small

Broader DTP definition includes manufacturer-sponsored direct access, cash-pay/discount pathways, home delivery, and patient access support programs

TAs with meaningful patient-direct access activity


Broader definition captures direct fulfillment, cash-pay, affordability and patient support pathways



Update: DTP/patient-direct activity now spans at least 5 TAs, but high-volume direct-fill activity remains led by obesity and cardiometabolic brands

DTP penetration & program breadth

Updated stats using broader definition; fulfillment penetration remains directional




LillyDirect as % of US Zepbound Rx
Directional range; remains the highest visible DTP penetration example
Lilly continues to cite LillyDirect as a scalable platform, but not updated share

3 True multi-brand DTP platforms

~5 Additional direct-access/fulfillment programs

Source: IQVIA analysis of public manufacturer programs and press releases, updated July 2026. Broader DTP definition includes manufacturer-sponsored direct access, cash-pay, direct fulfillment, and patient support programs. Counts and penetration ranges are directional and should be reconciled with IQVIA channel tracking before final publication

340B program growth accelerated in 2024 and 2025, as covered entity hospital systems expanded utilization



For many 340B claims, rebates are paid on top of the upfront discount

Rapid program growth creates significant drag on pharma finances

By comparison, 340B is already 2.5x total Medicaid and closing in on total Medicare Part D

Source: IQVIA GTN Solutions & Market Access Strategy Consulting analysis, DDD Data @ WAC \$

The 340B rebate model is a new way of effectuating discounts in the 340B Drug Pricing Program


An intense debate has arisen between rebate critics and advocates



Rebate critics

"...rebate schemes...would impose crushing financial burdens on safety-net hospitals"¹

"Plaintiffs allege irreparable harm for the costs they will incur from the Rebate Program between floating the upfront costs of covered drugs (far in excess of the costs they will ultimately be responsible for)..."²



Rebate advocates




"A transparent, rebate-based model, like the one proposed by HRSA...could be a first step towards mitigating the program's cost impact on working families"²

1. [Drugmakers' 340B rebate schemes threaten massive financial harm to safety-net hospitals](#). July 18, 2025. 340B Health.
2. American Hospital Association v. Kennedy. [No. 2:25-cv-00600 \(LEW\)](#), (D. Me.). December 29, 2025.
3. [HRSA 340B Rebate Model RFI Final Comments National Alliance 4-20-2026](#). National Alliance of Healthcare Purchaser Coalitions. April 20, 2026.



Wrap Up




Industry pipelines have herded into oncology, immunology, and neurology



Clinical Trial Starts per year Across Therapy Areas

Includes Phase 1-3 trials; global




Rare & orphan drugs have made up more **than 50% of Novel Active Substance approvals** since 2020

Over the past decade, there have been **155 NAS launches in oncology with +350 follow-on indications** totaling more than 500

U.S. median annualized treatment cost of **new oncology medicines in 2024 = \$411,855**

*Excludes gastrointestinal launches; **Excludes pain centered;
Source: IQVIA Institute, Mar 2026; Citeline Trialtrove; IQVIA Institute, Mar 2026;

A major wave of exclusivity losses is poised to reshape the market through 2029




Estimated LOE Year


The upcoming MFP products will heavily impact retail in 2027 while the 2028 will shift more toward Mail and Non-Retail

MAT Ending June 2026 Sales - Share by Channel - Sorted by % of Sales in Retail

2027 MFP Products



2028 MFP Products



Outlook to 2030

1

Spending growth

U.S. medicine spending is forecast to grow 4.5–7.5% through 2030, lifted by novel drugs and offset by expiries and price cuts

2

Policy impact

U.S. policy changes affecting spending and use of medicines are beginning to have clearer impacts

3

Exclusivity losses

Impact rises to \$111.7Bn over five years, driven by significant patent expiries beginning in 2028

4

Growth drivers

Oncology and obesity drive growth through 2030, while diabetes, immunology and hematology contribute to slowing

5

Immunology

Spending growth slows to 4–7% through 2030 on biosimilar impact and slowing volume growth

6

Cell and gene therapy

Spending is expected to reach \$12.5Bn by 2030, more than double the current level

Source: <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026>

Some Trends to Watch in 2027

Medicare Pressures

**Mega-blockbusters
Dominate Growth**

**GLP-1s Reshape
Entire Markets**

**Rising
Consumerism**

**Commercial Impact of
AI & Tech**



PBM Reforms Loom

**Modern Launch
Challenges**

**Pricing
Volatility**

LOEs Reshape Markets

**Pipeline Herding Leads
to Hypercompetition**

Meet the Industry Relations Team 2026



Scott Biggs

Director, Supplier Services



David Mennen

Analyst, Supplier Services



Scott Biggs

Director, Supplier Services, IQVIA

scott.biggs@iqvia.com

717.585.8503


.....

Scott serves as a Director in the Supplier Services Group at IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services tailored for the life sciences and healthcare sectors. IQVIA's mission is to enhance patient outcomes by fostering healthcare innovations through its data, technology, and expertise. By integrating big data, advanced analytics, and industry knowledge, IQVIA assists clients in making informed decisions and speeding up the development of groundbreaking treatments.

He initiated his career in the pharmacy field at Rite Aid, where he undertook various roles with escalating responsibilities. Prior to joining IQVIA in 2011, he was employed by other pharmaceutical information firms like Verispan and SDI. Scott holds a BS degree in Accounting from Penn State University and has nearly three decades of experience working with pharmacy data. In his capacity at IQVIA, Scott collaborates with retailers, software vendors, and various data suppliers, helping them gain insights into their market performance through business reviews and market analysis.

Scott resides in Ludington, MI, with his wife and three children. He enjoys woodworking, honing his shooting skills, and volunteering. He actively contributes to his community through service on county boards, involvement with his church, and with the Mason County Sheriff's Office. Additionally, Scott and his wife are dedicated advocates for organizations aimed at combating human trafficking. Scott is also an Army Veteran who served in the U.S. Army Reserves and Pennsylvania Army National Guard.

Scan to receive a copy of the IQVIA presentation: 2026
Pharmaceutical Trends, Issues and Forecasts



Click this box on the site

Questions and Answers

Please submit your questions using the Q&A feature
at the bottom of your screen

Next Webinar



Q4 Member Webinar

October 28 @ 1pm ET

Members Only

Registration Open



PQA Workshop: Using the PQA Medication Therapy Problem Categories Framework in Practice

An In-Person Education Program with Interactive, Case-Based Learning

November 5 @ 9 – 1:30pm ET

Renaissance Arlington Capital View Hotel

Registration Open

PQA26 LEADERSHIP SUMMIT

November 5 – 6, 2026

2026 PQA Leadership Summit

Coming Soon



2027 PQA Annual Meeting Call for Proposals

Breakout Sessions

Poster Abstracts



Pharmacy Trends, Issues and Forecasts

October 8, 2026